3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
13
Gastrointestinal
7
Breast
3
Thoracic
2
Sarcoma
1
Plasma cell
1
Myeloid
1
Head & Neck
1
Genitourinary
1
CNS
1
Conditions
Urinary Bladder Neoplasms
157
Carcinoma, Transitional Cell
56
Non-Muscle Invasive Bladder Neoplasms
30
Urethral Neoplasms
24
Carcinoma, Renal Cell
23
Neoplasms
19
Kidney Neoplasms
15
Pancreatic Neoplasms
14
Ovarian Neoplasms
14
Neoplasm Metastasis
13
Carcinoma, Non-Small-Cell Lung
13
Prostatic Neoplasms
12
Ureteral Neoplasms
11
Urologic Neoplasms
9
Colorectal Neoplasms
9
Breast Neoplasms
9
Lung Neoplasms
7
Testicular Neoplasms
6
Stomach Neoplasms
6
Melanoma
6
Sarcoma
5
Urothelial Cancer
4
Squamous Cell Carcinoma of Head and Neck
4
Small Cell Lung Carcinoma
4
Osteosarcoma
4
Colonic Neoplasms
4
Urogenital Neoplasms
3
Triple Negative Breast Neoplasms
3
Recurrence
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Interventions
pembrolizumab
18
Nivolumab
6
Radiotherapy
5
Paclitaxel
5
Trastuzumab
4
Specimen Handling
4
Ipilimumab
4
tisotumab vedotin
3
temsirolimus
3
olaparib
3
lenvatinib
3
X-Rays
3
Taxes
3
Surveys and Questionnaires
3
Early Intervention, Educational
3
Cyclophosphamide
3
Carboplatin
3
Biopsy
3
spartalizumab
2
sargramostim
2
rucaparib
2
palbociclib
2
fludarabine
2
epacadostat
2
enzalutamide
2
durvalumab
2
cabozantinib
2
atezolizumab
2
aflibercept
2
Vinorelbine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Gemcitabine
×
Genitourinary
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled